Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 7Gastrointestinal Stromal Tumors 5Urologic Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Carcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

anlotinib 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Renal Cancer × Sunitinib × Clear all
NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Active not recruiting
528 enrolled

Advanced Renal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡